Aurinia Pharmaceuticals Inc. (AUPH): Total Assets
$751.59M
As of 2025-12-31
$792.26M
As of 2026-06-30
+16.9%
3-year compound annual growth
+10.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $751.59M | +36.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $550.64M | +0.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $548.06M | +16.4% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $470.86M | -13.3% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $543.37M | +17.2% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $463.66M | +43.0% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $324.30M | n/a | 2021-02-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $751.59M | +36.5% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $751.18M | +72.5% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $763.63M | +31.5% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $764.99M | +8.7% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $738.36M | -2.9% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $734.73M | +12.1% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $770.58M | -23.6% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $777.78M | +27.8% |
Compare AUPH, SMMT, KNSA, CYRX side by side · Screen every company in Pharmaceutical Preparations ↗